Evaluation of SARS-CoV-2 Seroprevalence and Variant Distribution During the Delta–Omicron Transmission Waves in Greater Accra, Ghana, 2021
Viruses · 2025
DOI: 10.3390/v17040487 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2025. Verfasst von Elvis Suatey Lomotey und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon, Accra P.O. Box LG 581, Ghana. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bill & Melinda Gates Foundation, African Academy of Sciences, World Health Organization.
Abstract (Originalsprache)
A significant proportion of SARS-CoV-2 infections in Africa were identified as asymptomatic. With the surge of the Omicron variant, asymptomatic participants in epidemiological surveys were key to accurately estimating seroprevalence and true infections in the population. This study assessed seroprevalence, active infections, and circulating variants in Accra, Ghana, during the Omicron wave. Secondary objectives included assessing the association between seroprevalence and sociodemographic factors, vaccination, and adherence to recommended SARS-CoV-2 prevention and control measures. We conducted a cross-sectional survey in Greater Accra in December 2021 using a standardized questionnaire. Serum and naso-oropharyngeal swab samples were collected from 1027 individuals aged ≥ 5 years for the estimation of total antibodies and detection of infection. The study found an overall seroprevalence of 86.8% [95% CI: 84.53–88.77]. PCR test positivity of SARS-CoV-2 was 10%, with the Omicron and Delta variants accounting for 44.1% and 8.8% of infections, respectively. Vaccination (cOR = 10.5, 95% CI: 4.97–26.9, p < 0.001) and older age, particularly the 60+ age group (cOR = 6.05, 95% CI: 2.44–20.2, p < 0.001), were associated with an increase in odds of seropositivity among participants. High seropositivity of SARS-CoV-2 in Accra was an indication of high exposure and transmission rates and/or high vaccine-induced seroprevalence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon, Accra P.O. Box LG 581, Ghana.
- Department of Parasitology, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon, Accra P.O. Box LG 581, Ghana.
ORCID-Profile: Elvis Suatey Lomotey, Jewelna Akorli, Daniel Adjei Odumang, Kojo Nketia, Emmanuel Frimpong Gyekye, Yvonne Ashong, Benjamin Abuaku, Irene Owusu Donkor
Förderung
- Bill & Melinda Gates Foundation
- African Academy of Sciences
- World Health Organization
- Bill and Melinda Gates Foundation
- The Bill and Melinda Gates Foundation
Zitieren
APA
Lomotey, E. S., Akorli, J., Opoku, M., Odumang, D. A., Nketia, K., Gyekye, E. F., Sedzro, K. M., Andoh, N. E., Ashong, Y., Abuaku, B., Koram, K. A., & Owusu Donkor, I. (2025). Evaluation of SARS-CoV-2 Seroprevalence and Variant Distribution During the Delta–Omicron Transmission Waves in Greater Accra, Ghana, 2021. Viruses. https://doi.org/10.3390/v17040487
Vancouver
Lomotey ES, Akorli J, Opoku M, Odumang DA, Nketia K, Gyekye EF, et al. Evaluation of SARS-CoV-2 Seroprevalence and Variant Distribution During the Delta–Omicron Transmission Waves in Greater Accra, Ghana, 2021. Viruses. 2025. doi:10.3390/v17040487
BibTeX
@article{Lomotey2025,
author = {Lomotey, Elvis Suatey and Akorli, Jewelna and Opoku, Millicent and Odumang, Daniel Adjei and Nketia, Kojo and Gyekye, Emmanuel Frimpong and Sedzro, Kojo Mensah and Andoh, Nana Efua and Ashong, Yvonne and Abuaku, Benjamin and Koram, Kwadwo A and Owusu Donkor, Irene},
title = {Evaluation of SARS-CoV-2 Seroprevalence and Variant Distribution During the Delta–Omicron Transmission Waves in Greater Accra, Ghana, 2021},
journal = {Viruses},
year = {2025},
doi = {10.3390/v17040487}
}
EUVIMED